OncoMatch

OncoMatch/Clinical Trials/NCT04469764

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Is NCT04469764 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Abemaciclib and Anastrozole for recurrent endometrial carcinoma.

Phase 2RecruitingJonsson Comprehensive Cancer CenterNCT04469764Data as of May 2026

Treatment: Abemaciclib · Anastrozole · LetrozoleThis phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Endometrial Cancer

Ovarian Cancer

Biomarker criteria

Required: CDK4 activation features

demonstrates CDK4/6 activation features

Required: CDK6 activation features

demonstrates CDK4/6 activation features

Excluded: CCNE1 amplification

lack of Cyclin E gene (CCNE) amplification

Excluded: RB1 loss

lack of ... retinoblastoma susceptibility gene product (RB) loss

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: chemotherapy — recurrent ovarian or endometrial cancer

At least one prior chemotherapy regimen for the treatment of recurrent ovarian or endometrial cancer

Lab requirements

Blood counts

ANC ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 8 g/dL (transfusion permitted, treatment must not begin earlier than the day after transfusion)

Liver function

Total bilirubin ≤ 1.5 x ULN (Gilbert's syndrome: ≤ 2.0 x ULN and direct bilirubin within normal limits); ALT and AST ≤ 3 x ULN

Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 8 g/dL ... Total bilirubin ≤ 1.5 x ULN ... ALT and AST ≤ 3 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify